Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity

Cell

Volumn 165, Issue 7, 2016, Pages 1621-1631

  Huang, Yaoxing ^a   Yu, Jian ^a   Lanzi, Anastasia ^a   Yao, Xin ^a   Andrews, Chasity D ^a   Tsai, Lily ^a   Gajjar, Mili R ^a   Sun, Ming ^a   Seaman, Michael S ^b   Padte, Neal N ^a   Ho, David D ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; GLYCOPROTEIN GP 160; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY ENGINEERING; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; GEOGRAPHIC ORIGIN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; VIRUS LOAD; VIRUS NEUTRALIZATION; ANIMAL; CHEMISTRY; HIV INFECTIONS; HUMAN; IMMUNOLOGY;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, PASSIVE; MICE;

EID: 84975221851     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2016.05.024     Document Type: Article

References (53)

1. C.D. Andrews, W.R. Spreen, H. Mohri, L. Moss, S. Ford, A. Gettie, K. Russell-Lodrigue, R.P. Bohm, C. Cheng-Mayer, Z. Hong, and et al. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus Science 343 2014 1151 1154
2. J.M. Baeten, J.E. Haberer, A.Y. Liu, and N. Sista Preexposure prophylaxis for HIV prevention: where have we been and where are we going? J. Acquir. Immune Defic. Syndr. 63 Suppl 2 2013 S122 S129
3. A.B. Balazs, J. Chen, C.M. Hong, D.S. Rao, L. Yang, and D. Baltimore Antibody-based protection against HIV infection by vectored immunoprophylaxis Nature 481 2012 81 84
4. A.B. Balazs, Y. Ouyang, C.M. Hong, J. Chen, S.M. Nguyen, D.S. Rao, D.S. An, and D. Baltimore Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission Nat. Med. 20 2014 296 300
5. D.H. Barouch, J.B. Whitney, B. Moldt, F. Klein, T.Y. Oliveira, J. Liu, K.E. Stephenson, H.W. Chang, K. Shekhar, S. Gupta, and et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys Nature 503 2013 224 228
6. B.K. Berges, and M.R. Rowan The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment Retrovirology 8 2011 65
7. C. Blattner, J.H. Lee, K. Sliepen, R. Derking, E. Falkowska, A.T. de la Peña, A. Cupo, J.P. Julien, M. van Gils, P.S. Lee, and et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers Immunity 40 2014 669 680
8. L.C. Burkly, D. Olson, R. Shapiro, G. Winkler, J.J. Rosa, D.W. Thomas, C. Williams, and P. Chisholm Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion J. Immunol. 149 1992 1779 1787
9. M. Caskey, F. Klein, J.C. Lorenzi, M.S. Seaman, A.P. West Jr., N. Buckley, G. Kremer, L. Nogueira, M. Braunschweig, J.F. Scheid, and et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 Nature 522 2015 487 491
10. R. Diskin, J.F. Scheid, P.M. Marcovecchio, A.P. West Jr., F. Klein, H. Gao, P.N. Gnanapragasam, A. Abadir, M.S. Seaman, M.C. Nussenzweig, and P.J. Bjorkman Increasing the potency and breadth of an HIV antibody by using structure-based rational design Science 334 2011 1289 1293
11. N.A. Doria-Rose, C.A. Schramm, J. Gorman, P.L. Moore, J.N. Bhiman, B.J. DeKosky, M.J. Ernandes, I.S. Georgiev, H.J. Kim, M. Pancera, et al. NISC Comparative Sequencing Program Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies Nature 509 2014 55 62
12. E. Falkowska, K.M. Le, A. Ramos, K.J. Doores, J.H. Lee, C. Blattner, A. Ramirez, R. Derking, M.J. van Gils, C.H. Liang, and et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers Immunity 40 2014 657 668
13. M.R. Gardner, L.M. Kattenhorn, H.R. Kondur, M. von Schaewen, T. Dorfman, J.J. Chiang, K.G. Haworth, J.M. Decker, M.D. Alpert, C.C. Bailey, and et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges Nature 519 2015 87 91
14. I.S. Georgiev, R.S. Rudicell, K.O. Saunders, W. Shi, T. Kirys, K. McKee, S. O'Dell, G.Y. Chuang, Z.Y. Yang, G. Ofek, and et al. Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline J. Immunol. 192 2014 1100 1106
15. A.M. Goetze, M.R. Schenauer, and G.C. Flynn Assessing monoclonal antibody product quality attribute criticality through clinical studies MAbs 2 2010 500 507
16. A. Halper-Stromberg, C.L. Lu, F. Klein, J.A. Horwitz, S. Bournazos, L. Nogueira, T.R. Eisenreich, C. Liu, A. Gazumyan, U. Schaefer, and et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice Cell 158 2014 989 999
17. M. Haverick, S. Mengisen, M. Shameem, and A. Ambrogelly Separation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: overview and applications MAbs 6 2014 852 858
18. J. Huang, G. Ofek, L. Laub, M.K. Louder, N.A. Doria-Rose, N.S. Longo, H. Imamichi, R.T. Bailer, B. Chakrabarti, S.K. Sharma, and et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody Nature 491 2012 406 412
19. K.M. Hutterer, R.W. Hong, J. Lull, X. Zhao, T. Wang, R. Pei, M.E. Le, O. Borisov, R. Piper, Y.D. Liu, and et al. Monoclonal antibody disulfide reduction during manufacturing: Untangling process effects from product effects MAbs 5 2013 608 613
20. J.M. Jacobson, D.R. Kuritzkes, E. Godofsky, E. DeJesus, J.A. Larson, S.P. Weinheimer, and S.T. Lewis Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults Antimicrob. Agents Chemother. 53 2009 450 457
21. F. Klein, A. Halper-Stromberg, J.A. Horwitz, H. Gruell, J.F. Scheid, S. Bournazos, H. Mouquet, L.A. Spatz, R. Diskin, A. Abadir, and et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice Nature 492 2012 118 122
22. R. Kong, M.K. Louder, K. Wagh, R.T. Bailer, A. deCamp, K. Greene, H. Gao, J.D. Taft, A. Gazumyan, C. Liu, and et al. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes J. Virol. 89 2015 2659 2671
23. K.L. Koterba, T. Borgschulte, and M.W. Laird Thioredoxin 1 is responsible for antibody disulfide reduction in CHO cell culture J. Biotechnol. 157 2012 261 267
24. H. Liu, G. Gaza-Bulseco, D. Faldu, C. Chumsae, and J. Sun Heterogeneity of monoclonal antibodies J. Pharm. Sci. 97 2008 2426 2447
25. D. Lowe, K. Dudgeon, R. Rouet, P. Schofield, L. Jermutus, and D. Christ Aggregation, stability, and formulation of human antibody therapeutics Adv. Protein Chem. Struct. Biol. 84 2011 41 61
26. X.M. Luo, M.Y. Lei, R.A. Feidi, A.P. West Jr., A.B. Balazs, P.J. Bjorkman, L. Yang, and D. Baltimore Dimeric 2G12 as a potent protection against HIV-1 PLoS Pathog. 6 2010 e1001225
27. R.M. Lynch, E. Boritz, E.E. Coates, A. DeZure, P. Madden, P. Costner, M.E. Enama, S. Plummer, L. Holman, C.S. Hendel, et al. VRC 601 Study Team Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection Sci. Transl. Med. 7 2015 319ra206
28. J.R. Mascola, and B.F. Haynes HIV-1 neutralizing antibodies: understanding nature's pathways Immunol. Rev. 254 2013 225 244
29. H. Mouquet, L. Scharf, Z. Euler, Y. Liu, C. Eden, J.F. Scheid, A. Halper-Stromberg, P.N. Gnanapragasam, D.I. Spencer, M.S. Seaman, and et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies Proc. Natl. Acad. Sci. USA 109 2012 E3268 E3277
30. H. Mouquet, M. Warncke, J.F. Scheid, M.S. Seaman, and M.C. Nussenzweig Enhanced HIV-1 neutralization by antibody heteroligation Proc. Natl. Acad. Sci. USA 109 2012 875 880
31. B. Mullan, B. Dravis, A. Lim, A. Clarke, S. Janes, P. Lambooy, D. Olson, T. O'Riordan, B. Ricart, and A.G. Tulloch Disulphide bond reduction of a therapeutic monoclonal antibody during cell culture manufacturing operations BMC Proc. 5 Suppl 8 2011 110
32. W.C. Olson, P.J. Maddon, N. Tsurushita, P.R. Hinton, and M. Vasquez Anti-CCR5 antibody United States Patent and Trademark Office 2003 Progenics Pharmaceuticals, Inc. and PDL Biopharma, Inc. United States Patent and Trademark Office US patent US7122185 B2
33. C.S. Pace, M.W. Fordyce, D. Franco, C.Y. Kao, M.S. Seaman, and D.D. Ho Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope J. Acquir. Immune Defic. Syndr. 62 2013 1 9
34. C.S. Pace, R. Song, C. Ochsenbauer, C.D. Andrews, D. Franco, J. Yu, D.A. Oren, M.S. Seaman, and D.D. Ho Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1 Proc. Natl. Acad. Sci. USA 110 2013 13540 13545
35. L.J. Reed, and H. Muench A simple method of estimating fifty percent endpoints Am. J. Hyg. 27 1938 493 497
36. K.A. Reimann, W. Lin, S. Bixler, B. Browning, B.N. Ehrenfels, J. Lucci, K. Miatkowski, D. Olson, T.H. Parish, M.D. Rosa, and et al. A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties AIDS Res. Hum. Retroviruses 13 1997 933 943
37. S. Rosati, Y. Yang, A. Barendregt, and A.J. Heck Detailed mass analysis of structural heterogeneity in monoclonal antibodies using native mass spectrometry Nat. Protoc. 9 2014 967 976
38. R.S. Rudicell, Y.D. Kwon, S.Y. Ko, A. Pegu, M.K. Louder, I.S. Georgiev, X. Wu, J. Zhu, J.C. Boyington, X. Chen, et al. NISC Comparative Sequencing Program Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo J. Virol. 88 2014 12669 12682
39. B.A. Salinas, H.A. Sathish, A.U. Shah, J.F. Carpenter, and T.W. Randolph Buffer-dependent fragmentation of a humanized full-length monoclonal antibody J. Pharm. Sci. 99 2010 2962 2974
40. W. Schaefer, J.T. Regula, M. Bähner, J. Schanzer, R. Croasdale, H. Dürr, C. Gassner, G. Georges, H. Kettenberger, S. Imhof-Jung, and et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies Proc. Natl. Acad. Sci. USA 108 2011 11187 11192
41. J.F. Scheid, H. Mouquet, B. Ueberheide, R. Diskin, F. Klein, T.Y. Oliveira, J. Pietzsch, D. Fenyo, A. Abadir, K. Velinzon, and et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding Science 333 2011 1633 1637
42. M.S. Seaman, H. Janes, N. Hawkins, L.E. Grandpre, C. Devoy, A. Giri, R.T. Coffey, L. Harris, B. Wood, M.G. Daniels, and et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies J. Virol. 84 2010 1439 1452
43. D. Sok, M.J. van Gils, M. Pauthner, J.P. Julien, K.L. Saye-Francisco, J. Hsueh, B. Briney, J.H. Lee, K.M. Le, P.S. Lee, and et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex Proc. Natl. Acad. Sci. USA 111 2014 17624 17629
44. R. Song, D. Franco, C.Y. Kao, F. Yu, Y. Huang, and D.D. Ho Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients J. Virol. 84 2010 6935 6942
45. G. Stiegler, R. Kunert, M. Purtscher, S. Wolbank, R. Voglauer, F. Steindl, and H. Katinger A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1 AIDS Res. Hum. Retroviruses 17 2001 1757 1765
46. M. Sun, C.S. Pace, X. Yao, F. Yu, N.N. Padte, Y. Huang, M.S. Seaman, Q. Li, and D.D. Ho Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36 J. Acquir. Immune Defic. Syndr. 66 2014 473 483
47. A.R. Tenorio The monoclonal CCR5 antibody PRO-140: the promise of once-weekly HIV therapy Curr. HIV/AIDS Rep. 8 2011 1 3
48. J. Toma, S.P. Weinheimer, E. Stawiski, J.M. Whitcomb, S.T. Lewis, C.J. Petropoulos, and W. Huang Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab J. Virol. 85 2011 3872 3880
49. A. Trkola, T.J. Ketas, K.A. Nagashima, L. Zhao, T. Cilliers, L. Morris, J.P. Moore, P.J. Maddon, and W.C. Olson Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140 J. Virol. 75 2001 579 588
50. L.M. Walker, S.K. Phogat, P.Y. Chan-Hui, D. Wagner, P. Phung, J.L. Goss, T. Wrin, M.D. Simek, S. Fling, J.L. Mitcham, et al. Protocol G Principal Investigators Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target Science 326 2009 285 289
51. L.M. Walker, M. Huber, K.J. Doores, E. Falkowska, R. Pejchal, J.P. Julien, S.K. Wang, A. Ramos, P.Y. Chan-Hui, M. Moyle, et al. Protocol G Principal Investigators Broad neutralization coverage of HIV by multiple highly potent antibodies Nature 477 2011 466 470
52. X. Wu, Z.Y. Yang, Y. Li, C.M. Hogerkorp, W.R. Schief, M.S. Seaman, T. Zhou, S.D. Schmidt, L. Wu, L. Xu, and et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 Science 329 2010 856 861
53. J. Zhu, G. Ofek, Y. Yang, B. Zhang, M.K. Louder, G. Lu, K. McKee, M. Pancera, J. Skinner, Z. Zhang, et al. NISC Comparative Sequencing Program Mining the antibodyome for HIV-1-neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains Proc. Natl. Acad. Sci. USA 110 2013 6470 6475